新型 CRISPR 療法在降低膽固醇方面取得成功
New CRISPR Therapy Shows Success in Reducing Cholesterol
Updated at: September 29, 2026 at 02:15 AM
醫學界正處於心臟疾病治療革命的邊緣。
Medical science is on the brink of a revolution in treating heart disease.
過去管理高膽固醇通常需要患者終身服用每日藥丸或定期注射。
Traditionally, managing high cholesterol has required patients to take daily pills or receive regular injections for their entire lives.
透過精準的基因編輯技術，科學家現在能夠「關閉」肝臟中調節脂質水平的特定基因。
By using precise gene-editing technology, scientists can now 'switch off' specific genes in the liver that regulate lipid levels.
這種方法模仿了在某些健康個體中發現的罕見保護性基因突變。
This method mimics rare, protective genetic mutations found in some healthy individuals.
針對CTX310療法的近期試驗展現出驚人的前景。
Recent trials for the therapy CTX310 have shown incredible promise.
單次輸注即成功將患者的低密度脂蛋白膽固醇降低了50%以上，且效果持續至少一年，且未報告嚴重安全問題。
A single infusion successfully reduced LDL cholesterol by over 50% in patients, with results lasting at least one year and no serious safety issues reported.
儘管其他針對PCSK9基因的治療面臨臨床障礙，但該領域仍持樂觀態度。
While other treatments, like those targeting the PCSK9 gene, have faced clinical hurdles, the field remains optimistic.
這些基因編輯療法旨在協助患有嚴重且對藥物有抗藥性之脂質障礙的患者。
These gene-editing treatments aim to help people with severe, medication-resistant lipid disorders.
雖然監管機構因治療的永久性而要求長期監測，但早期結果被形容為「前所未有」。
Although regulatory bodies mandate long-term monitoring due to the permanent nature of the treatment, early results are described as 'unprecedented.'
若未來試驗證實了這些發現，我們或許將迎來一個以單一永久基因調整，而非終身服藥來控制心血管風險的未來。
If future trials confirm these findings, we may see a future where cardiovascular risk is managed by a single, permanent genetic adjustment rather than a lifetime of medication.
